Zhongwu Li Selected Research

Cisplatin (Platino)

1/2018	Wee1 Inhibitor AZD1775 Combined with Cisplatin Potentiates Anticancer Activity against Gastric Cancer by Increasing DNA Damage and Cell Apoptosis.
4/2017	Irinotecan plus cisplatin followed by octreotide long-acting release maintenance treatment in advanced gastroenteropancreatic neuroendocrine carcinoma: IPO-NEC study.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Zhongwu Li Research Topics

Disease

71	Neoplasms (Cancer) 05/2024 - 07/2009
32	Stomach Neoplasms (Stomach Cancer) 01/2023 - 11/2007
14	Carcinogenesis 01/2021 - 11/2007
12	Melanoma (Melanoma, Malignant) 05/2024 - 12/2010
11	Squamous Cell Carcinoma of Head and Neck 01/2022 - 01/2017
10	Neoplasm Metastasis (Metastasis) 02/2023 - 03/2015
7	Adenocarcinoma 01/2023 - 06/2018
7	Colorectal Neoplasms (Colorectal Cancer) 07/2022 - 01/2018
7	Breast Neoplasms (Breast Cancer) 04/2022 - 07/2009
5	Squamous Cell Carcinoma (Epidermoid Carcinoma) 07/2022 - 12/2014
4	Rectal Neoplasms (Rectal Cancer) 02/2024 - 10/2014
4	Microsatellite Instability 07/2022 - 11/2020
4	Esophageal Squamous Cell Carcinoma 01/2021 - 01/2015
3	Lung Neoplasms (Lung Cancer) 11/2019 - 12/2011
3	Neuroendocrine Tumors (Neuroendocrine Tumor) 05/2018 - 01/2015
3	Tongue Neoplasms (Tongue Neoplasm) 02/2015 - 12/2013
2	Extramammary Paget Disease (Paget Disease, Extramammary) 05/2024 - 07/2017
2	Disease Progression 02/2024 - 08/2011
2	Colonic Neoplasms (Colon Cancer) 01/2023 - 01/2020
2	Epstein-Barr Virus Infections 05/2021 - 01/2016
2	Hepatocellular Carcinoma (Hepatoma) 01/2019 - 08/2011
2	Pathologic Processes 05/2018 - 11/2007
2	Gastrointestinal Stromal Tumors (Gastrointestinal Stromal Tumor) 09/2017 - 01/2013
2	Mouth Neoplasms (Oral Cancer) 04/2016 - 01/2015
1	Sarcopenia 01/2023
1	Pathologic Complete Response 08/2022
1	Gastrointestinal Neoplasms (Gastrointestinal Cancer) 01/2022
1	Residual Neoplasm 01/2022
1	Solitary Fibrous Tumors 11/2021

Drug/Important Bio-Agent (IBA)

29	Biomarkers (Surrogate Marker)IBA 02/2024 - 08/2011
20	Proteins (Proteins, Gene)FDA Link 07/2022 - 07/2009
14	Messenger RNA (mRNA)IBA 01/2022 - 10/2013
8	Immune Checkpoint InhibitorsIBA 01/2022 - 10/2017
6	DNA (Deoxyribonucleic Acid)IBA 01/2021 - 08/2011
5	Monoclonal AntibodiesIBA 01/2023 - 01/2013
5	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 12/2022 - 12/2010
4	Trastuzumab (Herceptin)FDA Link 12/2022 - 11/2015
4	LigandsIBA 10/2022 - 11/2015
4	Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link 07/2022 - 08/2019
4	RNA (Ribonucleic Acid)IBA 01/2020 - 01/2016
3	Oxaliplatin (Eloxatin)FDA LinkGeneric 02/2024 - 08/2016
3	Circulating Tumor DNAIBA 01/2023 - 09/2017
3	B7-H1 AntigenIBA 04/2022 - 05/2018
3	Chromogranin AIBA 08/2021 - 01/2016
3	SynaptophysinIBA 08/2021 - 01/2018
3	ChromatinIBA 01/2021 - 12/2014
3	AfatinibIBA 11/2019 - 01/2018
3	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2019 - 11/2007
3	Histones (Histone)IBA 01/2019 - 12/2013
2	Capecitabine (Xeloda)FDA Link 02/2024 - 10/2018
2	ErbB Receptors (EGF Receptor)IBA 01/2024 - 07/2022
2	Epidermal Growth Factor (EGF)IBA 01/2024 - 09/2017
2	Small Interfering RNA (siRNA)IBA 11/2021 - 01/2018
2	NucleotidesIBA 06/2021 - 01/2016
2	CateninsIBA 01/2021 - 04/2017
2	Tumor Biomarkers (Tumor Markers)IBA 11/2020 - 01/2015
2	Formaldehyde (Formol)FDA Link 10/2020 - 11/2015
2	ParaffinIBA 10/2020 - 11/2015
2	PlatinumIBA 11/2019 - 08/2016
2	Long Noncoding RNAIBA 10/2019 - 01/2019
2	Antisense OligonucleotidesIBA 10/2019 - 01/2019
2	Antisense RNA (Anti-Sense RNA)IBA 10/2019 - 01/2019
2	Therapeutic UsesIBA 01/2019 - 01/2017
2	adavosertibIBA 06/2018 - 01/2018
2	Carrier Proteins (Binding Protein)IBA 06/2018 - 07/2017
2	Lysine (L-Lysine)FDA Link 05/2018 - 12/2013
2	Cetuximab (Erbitux)FDA Link 01/2018 - 10/2013
2	Polycomb Repressive Complex 2IBA 01/2018 - 01/2017
2	dactolisibIBA 01/2018 - 11/2015
2	Paclitaxel (Taxol)FDA LinkGeneric 01/2018 - 09/2014
2	Cisplatin (Platino)FDA LinkGeneric 01/2018 - 04/2017
2	Irinotecan (Camptosar)FDA LinkGeneric 12/2017 - 04/2017
2	Imatinib Mesylate (Gleevec)FDA Link 09/2017 - 05/2016
2	5-hydroxymethylcytosineIBA 08/2017 - 01/2016
2	Histone DemethylasesIBA 04/2016 - 02/2015
1	disitamab vedotinIBA 05/2024
1	Immunoconjugates (Immunoconjugate)IBA 05/2024
1	Trinitrotoluene (TNT)IBA 02/2024
1	camrelizumabIBA 02/2024
1	contrast agent BR1IBA 02/2023
1	SonazoidIBA 02/2023
1	Phosphotransferases (Kinase)IBA 11/2022
1	tyrosine receptor (receptor, tyrosine)IBA 11/2022
1	larotrectinibIBA 11/2022
1	entrectinibIBA 11/2022
1	ArrestinIBA 10/2022
1	human ERBB2 proteinIBA 07/2022
1	T-Cell Antigen Receptors (T-Cell Receptor)IBA 01/2022
1	Forkhead Transcription Factors (Forkhead Box Proteins)IBA 11/2021
1	NU 1025IBA 07/2021
1	Thiamine (Aneurin)FDA Link 07/2021

Therapy/Procedure

24	Therapeutics 05/2024 - 01/2013
12	Drug Therapy (Chemotherapy) 02/2023 - 07/2009
11	Neoadjuvant Therapy 02/2024 - 08/2016
7	Immunotherapy 05/2024 - 12/2020
3	Adjuvant Chemotherapy 01/2022 - 10/2018
2	Radiotherapy 01/2023 - 10/2014
2	Precision Medicine 01/2021 - 01/2017
1	Combined Modality Therapy 01/2023
1	Aftercare (After-Treatment) 08/2022